Search results for "double"

showing 10 items of 2879 documents

Objective analysis of contact lens fit.

2015

Purpose: To assess the validity and repeatability of objective compared to subjective contact lens fit analysis. Methods: Thirty-five subjects (aged 22.0. ±. 3.0 years) wore two different soft contact lens designs. Four lens fit variables: centration, horizontal lag, post-blink movement in up-gaze and push-up recovery speed were assessed subjectively (four observers) and objectively from slit-lamp biomicroscopy captured images and video. The analysis was repeated a week later. Results: The average of the four experienced observers was compared to objective measures, but centration, movement on blink, lag and push-up recovery speed all varied significantly between them (p 0.05). The 95% conf…

AdultMalegenetic structuresObjective analysisObjective assessmentCorneaDouble-Blind MethodStatisticsMyopiaHumansMathematicsFit/gap analysisBlinkingbusiness.industryObjective measurementReproducibility of ResultsGeneral MedicineRepeatabilityEquipment DesignContact Lenses HydrophilicCentrationConfidence intervalContact lensOphthalmologyFemaleNuclear medicinebusinessOptometryContact lensanterior eye : the journal of the British Contact Lens Association
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome

1998

In a multicenter, double-blind, parallel group trial, the efficacy of risperidone (RIS) was compared with a combination of haloperidol and amitriptyline (HAL/AMI) over 6 weeks in patients with coexisting psychotic and depressive symptoms with either a schizoaffective disorder, depressive type, a major depression with psychotic features, or a nonresidual schizophrenia with major depressive symptoms according to DSM-III-R criteria. A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6.9 mg RIS versus 9 mg HAL combined with 180 mg AMI. Efficacy results for those 98 patients (47 RIS; 51 HAL/AMI) who completed at least 3 weeks of double-blind treatme…

AdultMalemedicine.medical_specialtyAdolescentAmitriptylineSchizoaffective disorderAntidepressive Agents Tricycliclaw.inventionDouble-Blind MethodExtrapyramidal symptomsRandomized controlled triallawInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmitriptylinePsychiatryAgedPsychiatric Status Rating ScalesDepressive DisorderRisperidoneMiddle AgedRisperidonemedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaHaloperidolFemalemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-media…

2011

Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels50  mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600  mg/day or placebo in …

AdultMalemedicine.medical_specialtyAdolescentBrachial ArteryDalcetrapibCoronary DiseaseAtherosclerosis CETP inhibition Endothelial function Flow-mediated dilatation ester transfer protein density-lipoprotein cholesterol off-target toxicity cardiovascular-disease dependent vasodilation coronary risk nitric-oxide torcetrapib atherosclerosis cetpModels BiologicalPlaceboschemistry.chemical_compoundYoung AdultDouble-Blind Methodmedicine.arteryInternal medicineCholesterylester transfer proteinmedicineHumansSulfhydryl CompoundsBrachial arteryLipoprotein cholesterolFlow mediated vasodilatationAgedRationalizationbiologybusiness.industryAnticholesteremic AgentsEstersGeneral MedicineCetp inhibitionMiddle AgedAmidesCoronary heart diseaseClinical trialVasodilationTreatment OutcomechemistryRegional Blood FlowResearch DesignCardiologybiology.proteinlipids (amino acids peptides and proteins)FemaleEndothelium VascularbusinessAlgorithms
researchProduct

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbi…

2008

Summary Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. Objective The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. Methods A randomized, double-blind, placebo-controlled, multi-centre trial was performed to assess the efficacy and safety of omalizumab (Xolair®) vs. placebo in combination with depigmented SIT (Depigoid®) during the grass pollen season. Omalizumab or placebo was started 2 weeks befor…

AdultMalemedicine.medical_specialtyAdolescentCombination therapyImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedPlacebolaw.inventionYoung AdultPharmacotherapyDouble-Blind MethodRandomized controlled triallawForced Expiratory VolumeInternal medicineAnti-Allergic AgentsmedicineClinical endpointHumansImmunology and AllergyChildConjunctivitis AllergicAsthmaPlant Extractsbusiness.industryAntibodies MonoclonalRhinitis Allergic SeasonalAntigens PlantMiddle Agedmedicine.diseaseCombined Modality TherapyAsthmaAntibodies Anti-IdiotypicRespiratory Function TestsTreatment OutcomeDesensitization ImmunologicAsthma Control QuestionnaireQuality of LifePhysical therapyPollenFemalebusinessmedicine.drugClinical & Experimental Allergy
researchProduct

Rosiglitazone Causes Endothelial Dysfunction in Humans

2011

We explored the impact of rosiglitazone on endothelial function in normal volunteers and its interaction with glyceryl trinitrate (GTN)-induced abnormalities in endothelial function. We hypothesized that rosiglitazone would have a neutral effect on endothelial function in normal volunteers and would favorably modify endothelial dysfunction induced by GTN.In this double-blind, randomized, placebo-controlled study, 44 participants were randomized to placebo, rosiglitazone (4 mg twice daily), transdermal GTN (0.6 mg/h), or both GTN and rosiglitazone. After 7 days of treatment, participants underwent measures of forearm blood flow during brachial artery infusion of acetylcholine (Ach). Serum gl…

AdultMalemedicine.medical_specialtyAdolescentEndotheliumVasodilator AgentsBlood PressureVasodilationAscorbic AcidPharmacologyPlaceboRosiglitazoneNitroglycerinYoung AdultDouble-Blind MethodHeart RateInternal medicinemedicine.arterymedicineHumansPharmacology (medical)Endothelial dysfunctionBrachial arteryPharmacologyDose-Response Relationship Drugbusiness.industrymedicine.diseaseAscorbic acidAcetylcholineVasodilationmedicine.anatomical_structureBlood pressureEndocrinologycardiovascular systemThiazolidinedionesEndothelium VascularCardiology and Cardiovascular MedicineRosiglitazonebusinesscirculatory and respiratory physiologymedicine.drugJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Comparison of 4% articaine with epinephrine (1:100,000) and without epinephrine in inferior alveolar block for tooth extraction: double-blind randomi…

2011

The purpose of this clinical prospective, randomized, double-blind study was to compare the anesthetic efficacy of 4% articaine with epinephrine (1:100,000) and without epinephrine in inferior alveolar nerve block anesthesia for extractions of mandibular teeth.Eighty-eight patients received intraoral inferior alveolar nerve blocks using 4% articaine with 1:100,000 epinephrine (n = 41; group 1) or without epinephrine (n = 47; group 2) for extractions of mandibular teeth. The primary objectives were differences in onset as well as in length of soft tissue anesthesia. The amount of anesthetic solution, need of a second injection, pain while injecting, pain during treatment, postoperative pain,…

AdultMalemedicine.medical_specialtyAdolescentEpinephrineAnesthesia DentalMandibular NerveOperative TimeMandibular nerveCarticaineAnesthetic AgentInferior alveolar nerveArticainePathology and Forensic Medicinelaw.inventionYoung AdultCarticaineDouble-Blind MethodRandomized controlled triallawHumansVasoconstrictor AgentsMedicineRadiology Nuclear Medicine and imagingDentistry (miscellaneous)Prospective StudiesAnesthetics LocalAgedAged 80 and overPain PostoperativeChi-Square Distributionbusiness.industryNerve BlockMiddle AgedSurgeryEpinephrineAnesthesiaTooth ExtractionAnestheticFemaleSurgeryOral Surgerybusinessmedicine.drugOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
researchProduct